Edition:
United Kingdom

Vital Therapies Inc (VTL.OQ)

VTL.OQ on NASDAQ Stock Exchange Global Select Market

5.80USD
7:33pm BST
Change (% chg)

$-0.10 (-1.69%)
Prev Close
$5.90
Open
$5.90
Day's High
$5.95
Day's Low
$5.75
Volume
13,712
Avg. Vol
39,132
52-wk High
$7.20
52-wk Low
$2.25

Latest Key Developments (Source: Significant Developments)

Vital Therapies Announces Q4 Loss Per Share $0.35
Tuesday, 13 Mar 2018 

March 13 (Reuters) - Vital Therapies Inc ::VITAL THERAPIES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.35.Q4 EARNINGS PER SHARE VIEW $-0.31 -- THOMSON REUTERS I/B/E/S.BELIEVES ITS CURRENT CASH POSITION SHOULD PROVIDE FUNDING THROUGH Q1 OF 2019​.  Full Article

Vital Therapies Appoints Russell J. Cox As Chief Executive Officer And Board Member
Monday, 4 Dec 2017 

Dec 4 (Reuters) - Vital Therapies Inc ::VITAL THERAPIES APPOINTS RUSSELL J. COX AS CHIEF EXECUTIVE OFFICER AND BOARD MEMBER EFFECTIVE JANUARY 3, 2018.VITAL THERAPIES INC - COX WILL SUCCEED TERRY WINTERS.  Full Article

Vital Therapies reports Q3 loss per share $0.30
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - Vital Therapies Inc ::Vital therapies announces third quarter 2017 financial results.Q3 loss per share $0.30.Q3 earnings per share view $-0.32 -- Thomson Reuters I/B/E/S.Vital Therapies-believes current cash position could provide funding through q1 2019, past expected announcement of VTL-308 top-line trial results​.  Full Article

Vital Therapies Q2 loss per share $0.29
Thursday, 3 Aug 2017 

Aug 3 (Reuters) - Vital Therapies Inc ::Vital Therapies announces second quarter 2017 financial results.Q2 loss per share $0.29.Q2 earnings per share view $-0.35 -- Thomson Reuters I/B/E/S.Vital Therapies Inc - research and development expenses increased to $9.8 million for three months ended June 30 versus $6.9 million for 3 months ended June 30, 2016​.  Full Article

Vital Therapies announces Q1 loss per share $0.39
Tuesday, 9 May 2017 

May 9 (Reuters) - Vital Therapies Inc :Vital Therapies announces first quarter 2017 financial results.Q1 loss per share $0.39.Q1 earnings per share view $-0.37 -- Thomson Reuters I/B/E/S.  Full Article

Vital Therapies announces exercise in full of underwriters' option to purchase additional shares of common stock in public offering
Wednesday, 29 Mar 2017 

Vital Therapies Inc : Vital Therapies announces exercise in full of underwriters’ option to purchase additional shares of common stock in public offering . Vital Therapies Inc - underwriters have exercised in full their option to purchase an additional 1.3 million shares of its common stock .Vital Therapies Inc - Vital Therapies currently plans to use net proceeds from this offering for continuing clinical development of ELAD system.  Full Article

Vital Therapies announces pricing of public offering of common stock
Wednesday, 22 Mar 2017 

Vital Therapies Inc : Vital Therapies announces pricing of public offering of common stock .Says public offering of 8.75 million common shares priced at $4.00 per share.  Full Article

Vital Therapies announces proposed public offering of common stock
Tuesday, 21 Mar 2017 

Vital Therapies Inc : Vital Therapies announces proposed public offering of common stock .Vital Therapies Inc- plans to use net proceeds from offering for continuing clinical development of elad system.  Full Article

Vital Therapies Q4 loss per share $0.37
Tuesday, 7 Mar 2017 

Vital Therapies Inc : Vital Therapies announces fourth quarter and full year 2016 financial results . Q4 loss per share $0.37 . Q4 earnings per share view $-0.36 -- Thomson Reuters I/B/E/S .Vital Therapies Inc - company believes its cash position is sufficient to fund company through Q1 of 2018.  Full Article

Vital Therapies reports Q3 loss per share $0.32
Thursday, 3 Nov 2016 

Vital Therapies Inc : Vital therapies announces third quarter financial results . Q3 loss per share $0.32 .Q3 earnings per share view $-0.32 -- Thomson Reuters I/B/E/S.  Full Article